HomeCompareSNPHF vs SBUX

SNPHF vs SBUX: Dividend Comparison 2026

SNPHF yields 2.31% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $118.8K in total portfolio value
10 years
SNPHF
SNPHF
● Live price
2.31%
Share price
$10.99
Annual div
$0.25
5Y div CAGR
33.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.2K
Annual income
$8,450.71
Full SNPHF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — SNPHF vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNPHFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNPHF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNPHF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNPHF
Annual income on $10K today (after 15% tax)
$196.32/yr
After 10yr DRIP, annual income (after tax)
$7,183.10/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $53,282.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNPHF + SBUX for your $10,000?

SNPHF: 50%SBUX: 50%
100% SBUX50/50100% SNPHF
Portfolio after 10yr
$107.6K
Annual income
$39,793.58/yr
Blended yield
36.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

SNPHF
No analyst data
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNPHF buys
0
SBUX buys
0
No recent congressional trades found for SNPHF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNPHFSBUX
Forward yield2.31%2.84%
Annual dividend / share$0.25$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.6%48.3%
Portfolio after 10y$48.2K$167.0K
Annual income after 10y$8,450.71$71,136.45
Total dividends collected$24.8K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: SNPHF vs SBUX ($10,000, DRIP)

YearSNPHF PortfolioSNPHF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,009$308.57$11,121$420.68$112.00SBUX
2$12,203$424.14$12,548$648.40$345.00SBUX
3$13,645$587.05$14,440$1,013.98$795.00SBUX
4$15,419$819.56$17,068$1,617.30$1.6KSBUX
5$17,655$1,156.39$20,912$2,649.52$3.3KSBUX
6$20,544$1,653.23$26,875$4,499.29$6.3KSBUX
7$24,384$2,402.01$36,771$8,014.12$12.4KSBUX
8$29,651$3,559.74$54,542$15,197.11$24.9KSBUX
9$37,131$5,404.68$89,602$31,242.49$52.5KSBUX
10$48,181$8,450.71$167,011$71,136.45$118.8KSBUX

SNPHF vs SBUX: Complete Analysis 2026

SNPHFStock

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Full SNPHF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this SNPHF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNPHF vs SCHDSNPHF vs JEPISNPHF vs OSNPHF vs KOSNPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.